Zhengye Biotechnology Holding (ZYBT) Equity Average (2024 - 2025)
Zhengye Biotechnology Holding (ZYBT) reported Equity Average of $47.1 million for Q4 2025, down 2.07% year-over-year from $48.1 million in Q4 2024, and down 5.83% quarter-over-quarter from $50.0 million in Q2 2025.
Zhengye Biotechnology Holding (ZYBT) Equity Average (2024 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has 2 years of Equity Average data on file, last reported at $47.1 million in Q4 2025.
- Equity Average for Q4 2025 came in at $47.1 million, down 2.07% year-over-year; the trailing twelve-month figure through Dec 2025 was $47.1 million (down 2.07% YoY), and the FY2025 annual result was $41.4 million, down 3.8% from the prior year.
- Equity Average retreated to $47.1 million in Q4 2025 per ZYBT's latest filing, from $50.0 million in the prior quarter.
- Over five years, Equity Average peaked at $50.0 million in Q2 2025 and troughed at $47.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 8.07 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 3.32 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.50 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 409.63 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 3.33 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.52 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.79 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 493.55 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.15 Bn |
| 10 | Zhengye Biotechnology Holding | 5.49 Mn | 6.20 Mn | - | 47.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 47.10 Mn |
| Jun 30, 2025 | 50.02 Mn |
| Dec 31, 2024 | 48.10 Mn |